Startups, BioPharma

Ovarian cancer biotech Cynvec inches forward in $10 million round

New York-based biotech company, Cynvec, is currently raising capital to aid in the development of a vaccine designed to treat ovarian cancer.

The New York biotech company Cynvec gave the first indications it’s made progress on a $10 million funding round – raising $1.9 million of that goal, according to a recent regulatory filings.

The company is developing a vaccine designed to target ovarian cancer by boosting the body’s immune system and kill cancer cells. It’s currently in pre-clinical development with the treatment.

Company officials this week declined to discuss the round.

New York University professor Dr. Daniel Meruelo developed the treatment, called CYN-101. The vaccine uses a bio-engineered version of the Sindbis virus, which naturally gets transmitted to humans by mosquitoes and causes symptoms like joint pain and a rash. But the bio-engineered version is said to have anti-cancer properties and is being used to develop oncology drug immunotherapies.

The company was founded in 2004, received its first capital at the end of 2006, and previously raised about $5 million, according to regulatory filings.

Photo: Screenshot via Cynvec

Shares0
Shares0